Cynthia McCormick

TL;DR: In this article, the authors provide recommendations for the core outcome domains that should be considered by investigators conducting clinical trials of the efficacy and effectiveness of treatments for chronic pain, and develop a core set of outcome domains would facilitate comparison and pooling of d

TL;DR: A consensus meeting was convened by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) to provide recommendations for interpreting clinical importance of treatment outcomes in clinical trials of the efficacy and effectiveness of chronic pain treatments as discussed by the authors.

TL;DR: An initial examination of the psychometric properties of the Opioid Attractiveness Scale suggests that it is a valid and reliable scale that may be useful in providing important guidance on product features that are attractive to potential abusers.

TL;DR: A randomized, double-blind, multicenter, placebo-controlled trial of flunarizine in epileptic patients receiving concomitant phenytoin (PHT) or carbamazepine (CBZ), using a parallel rather than crossover design because of FNR's long half-life.

TL;DR: The patients receiving PHT (but not CBZ) tolerated higher plasma concentrations of ADD 94057 than did patients receiving CBZ, alone or in combination with PHT, and eight of nine patients had reductions in seizure frequency from baseline.